Tenaya Therapeutics, INC Schedule 13G passive stakes

Woodline Partners LP has disclosed a 4.99% beneficial ownership stake in Tenaya Therapeutics, Inc., primarily through warrants subject to a 4.99% ownership blocker.

Empery Asset Management, LP, along with Ryan M. Lane and Martin D. Hoe, reported a 4.99% beneficial ownership stake in Tenaya Therapeutics, Inc., including shares issuable from warrants, subject to a 4.99% ownership cap.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 1.7% beneficial ownership stake in Tenaya Therapeutics, Inc. as of June 30, 2025.

Woodline Partners LP has filed a Schedule 13G, revealing a beneficial ownership of 6.8% in Tenaya Therapeutics, Inc.'s common stock as of March 31, 2025.

Empery Asset Management, LP, along with Ryan M. Lane and Martin D. Hoe, has disclosed a collective beneficial ownership of 9.96% in Tenaya Therapeutics, Inc. as of March 31, 2025.

JPMorgan Chase & Co. has filed an amended Schedule 13G, reporting a beneficial ownership of 2.8% in Tenaya Therapeutics, Inc.'s common stock as of February 28, 2025.

RA Capital Management and its affiliates have filed an amended Schedule 13G, indicating they no longer hold any beneficial ownership in Tenaya Therapeutics, Inc. as of December 31, 2024.

JPMorgan Chase & Co. has filed a Schedule 13G, reporting a 6.5% beneficial ownership stake in Tenaya Therapeutics, Inc. as of December 31, 2024.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.7% beneficial ownership stake in Tenaya Therapeutics, Inc. as of December 31, 2024.